Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer’s disease

Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer’s disease

Abstract Background Lecanemab (BAN2401) is a humanized IgG1 monoclonal antibody that preferentially targets soluble aggregated Aβ species (protofibrils) with activity at insoluble fibrils and slowed clinical decline in an 18-month phase 2 proof-of-concept study (Study 201; ClinicalTrials.gov NCT0176...

Full description

Bibliographic Details
Main Authors: Shobha Dhadda, Michio Kanekiyo, David Li, Chad J. Swanson, Michael Irizarry, Scott Berry, Lynn D. Kramer, Donald A. Berry
Format: Article
Language:English
Published: BMC 2022-12-01
Series:Alzheimer’s Research & Therapy
Online Access:https://doi.org/10.1186/s13195-022-01129-x

Internet

https://doi.org/10.1186/s13195-022-01129-x

Similar Items